Released Mar 11, 2026, after the close
10-K filed Mar 11, 2026, 70 days after period end · 0001628280-26-016814
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$9.25M$9.25M derived+223.8% vs Q4 2024+13.4% vs Q3 2025
Net Income-$21.66M-$21.66M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$23,878,000N/M
Operating Cash Flowderived-$22,271,000N/M
Free Cash Flowderived-$22,271,000N/M
Margins · derived
Operating margin-258.2%+582.3 pt vs Q4 2024
Net margin-234.3%+448.6 pt vs Q4 2024
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $9.25M | $2.86M | $5.77M | $4.18M |
| Net Income | -$21.66M | -$19.50M | -$24.11M | -$28.89M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR